Literature DB >> 24333316

The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Gabriele Calizzani1, Samantha Profili1, Fabio Candura1, Monica Lanzoni2, Stefania Vaglio3, Livia Cannata1, Giancarlo M Liumbruno4, Massimo Franchini5, Pier Mannuccio Mannucci6, Giuliano Grazzini1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24333316      PMCID： PMC3853991          DOI： 10.2450/2013.011s

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  32 in total

1.  Clinical and organisational aspects of haemophilia care: the patients' view.

Authors:  Gabriele Calizzani; Romano Arcieri
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

2.  Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

3.  Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing.

Authors:  Giuliano Grazzini; Anna Ceccarelli; Deanna Calteri; Liviana Catalano; Gabriele Calizzani; Americo Cicchetti
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 4.  Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements.

Authors:  Mark W Skinner
Journal:  Br J Haematol       Date:  2011-06-28       Impact factor: 6.998

5.  Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.

Authors:  G C White; C W McMillan; H S Kingdon; C B Shoemaker
Journal:  N Engl J Med       Date:  1989-01-19       Impact factor: 91.245

6.  Mortality and causes of death in Italian persons with haemophilia, 1990-2007.

Authors:  A Tagliaferri; G F Rivolta; A Iorio; E Oliovecchio; M E Mancuso; M Morfini; A Rocino; M G Mazzucconi; M Franchini; N Ciavarella; A Scaraggi; L Valdrè; G Tagariello; P Radossi; G Muleo; P G Iannaccaro; C Biasoli; D Vincenzi; M L Serino; S Linari; C Molinari; E Boeri; M La Pecorella; M T Carloni; E Santagostino; G Di Minno; A Coppola; A Rocino; E Zanon; L Spiezia; C Di Perna; M Marchesini; M Marcucci; A Dragani; S Macchi; P Albertini; M D'Incà; C Santoro; F Biondo; G Piseddu; G Rossetti; G Barillari; G Gandini; A C Giuffrida; G Castaman
Journal:  Haemophilia       Date:  2010-02-09       Impact factor: 4.287

Review 7.  Hemophilia A in the third millennium.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Rev       Date:  2013-06-28       Impact factor: 8.250

8.  Haemophilia care in Europe - a survey of 35 countries.

Authors:  B O'Mahony; D Noone; P L F Giangrande; L Prihodova
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

9.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Authors:  Marilyn J Manco-Johnson; Thomas C Abshire; Amy D Shapiro; Brenda Riske; Michele R Hacker; Ray Kilcoyne; J David Ingram; Michael L Manco-Johnson; Sharon Funk; Linda Jacobson; Leonard A Valentino; W Keith Hoots; George R Buchanan; Donna DiMichele; Michael Recht; Deborah Brown; Cindy Leissinger; Shirley Bleak; Alan Cohen; Prasad Mathew; Alison Matsunaga; Desiree Medeiros; Diane Nugent; Gregory A Thomas; Alexis A Thompson; Kevin McRedmond; J Michael Soucie; Harlan Austin; Bruce L Evatt
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

10.  1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.

Authors:  P M Mannucci; Z M Ruggeri; F I Pareti; A Capitanio
Journal:  Lancet       Date:  1977-04-23       Impact factor: 79.321
View more
  7 in total

Review 1.  Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Liviana Catalano; Rosa Chianese; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 2.  Public expenditure for plasma-derived and recombinant medicinal products in Italy.

Authors:  Monica Lanzoni; Fabio Candura; Gabriele Calizzani; Claudia Biffoli; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 3.  Present and future challenges in the treatment of haemophilia: the patient's perspective.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  Plasma-derived medicinal products: demand and clinical use.

Authors:  Giuliano Grazzini; Pier Mannuccio Mannucci; Fabrizio Oleari
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 5.  Uncovered needs in the management of inherited bleeding disorders in Italy.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

6.  Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.

Authors:  Gabriele Calizzani; Ivana Menichini; Fabio Candura; Monica Lanzoni; Samantha Profili; Maria Rita Tamburrini; Antonio Fortino; Stefania Vaglio; Giuseppe Marano; Giuseppina Facco; Emily Oliovecchio; Massimo Franchini; Antonio Coppola; Romano Arcieri; Cinzia Bon; Mario Saia; Sabina Nuti; Massimo Morfini; Giancarlo M Liumbruno; Giovanni Di Minno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 7.  Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Authors:  Giovanni Di Minno; David Navarro; Carlo Federico Perno; Mariana Canaro; Lutz Gürtler; James W Ironside; Hermann Eichler; Andreas Tiede
Journal:  Ann Hematol       Date:  2017-06-18       Impact factor: 3.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.